Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Anstey, Nicholas M ^a   Auburn, Sarah A ^a   Kevin, Baird K ^b,aj   Battle, Katherine E ^c   Bobogare, Albino B ^d   Chancellor, Arna C ^e   Chasombat, Sanchai C ^f   Cheng, Qin C ^g   Domingo, Gonzalo J ^h   Drakeley, Christopher J ⁱ   Drukpa, Tobgyel D ^j   Dysoley, Lek D ^k,ak   Espino, Fe Esperanza ^l   Gething, Peter W ^c   Ghimire, Prakash G ^m,al   Gosling, Roly D ⁿ   Grewal Daumerie, Penny G D ^o   Hay, Simon I ^p,am,an   Howes, Rosalind E ^c,ao   Hwang, Jimee M ^n,q   Karim, Jahirul K ^r   Khan, Wasif Ali ^s   Kim, Jung Yeon ^t   Ley, Benedikt L ^a   Mannion, Kylie M ^a   McCarthy, James M ^e,u   Keong, Wan Ming ^j   Mueller, M Ivo ^v,ap   Namgay, Rinzin N ^w,aj   Price, Ric N ^a   Qi, Gao Q ^x   Rebueno, Marvi R ^y   Reeder, John R ^z,aq   Richards, Jack R ^z,ar   Sattabongkot Prachumsri, Jetsumon S P ^aa   Shanks, G Dennis ^e,g   Sibley, Carol Hopkins ^ab,am   Surya, Asik S ^ac   Taleo, George T ^ad   Thang, Ngo Duc ^ae   Thongpaseuth, Vonethalom T ^af   Thriemer, Kamala T ^a   Trimarsanto, Hidayat T ^ag   Vestergaard, Lasse S ^ah   Seidelein, Lorenz Von ^ai   Whittaker, Maxine W ^e   more..

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Ministry of Health and Medical Services   (Solomon Islands)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^h PATH   (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j Vector Borne Disease Sector Disease Control Programme   (South Africa)

^k National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^l DEPARTMENT OF HEALTH   (Philippines)

^m Ribhuvan University   (Nepal)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o Medicines for Malaria Venture   (Switzerland)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^r Directorate General of Health Services   (Bangladesh)

^s INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^t Division of Malaria and Parasitic Diseases   (United Kingdom)

^u QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^v WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^w Vector Borne Disease Control Programme   (Bhutan)

^x JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

^y Pilipinas Shell Foundation Inc   (Philippines)

^z BURNET INSTITUTE   (Australia)

^aa MAHIDOL UNIVERSITY   (Thailand)

^ab WorldWide Antimalarial Resistance Network   (United Kingdom)

^ac MINISTRY OF HEALTH   (Indonesia)

^ad Ministry of Health   (Vanuatu)

^ae National Institute of Malariology Parasitology and Entomology Hanoi   (Viet Nam)

^af Centre of Malariology Parasitology and Entomology   (Viet Nam)

^ag EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^ah ISSA Regional Office for Asia and the Pacific   (Philippines)

^ai MAHIDOL UNIVERSITY   (Thailand)

^aj UNIVERSITY OF OXFORD   (United Kingdom)

^ak National Institute of Public Health   (Cambodia)

^al WORLD HEALTH ORGANIZATION   (Switzerland)

^am UNIVERSITY OF WASHINGTON   (United States)

^an NATIONAL INSTITUTES OF HEALTH   (United States)

^ao CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ap CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^aq MONASH UNIVERSITY   (Australia)

^ar UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

APMEN; Asia Pacific; Elimination; Malaria; Plasmodium vivax

Indexed keywords

CHLOROQUINE;

ARTICLE; CONSENSUS; DISEASE SURVEILLANCE; DRUG EFFECT; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HISTORY; HUMAN; INVESTMENT; MALARIA CONTROL; NONHUMAN; PARASITE PREVALENCE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POINT OF CARE TESTING; PUBLIC HEALTH; TREATMENT PLANNING;

EID: 84949562890     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0958-y     Document Type: Article

References (67)

1. Douglas NM, Pontororing GJ, Lampah DA, Yeo TW, Kenangalem E, Poespoprodjo J, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med. 2014;12:217. doi: 10.1186/s12916-014-0217-z.
2. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36-57. doi: 10.1128/CMR.00074-12.
3. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, et al. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J. 2008;7:148. doi: 10.1186/1475-2875-7-148.
4. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965-7.
5. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis. 2009;48:1704-12. doi: 10.1086/599041.
6. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008;46:1374-81.
7. Imwong M, Hanchana S, Malleret B, Renia L, Day NP, Dondorp A, et al. High throughput ultra-sensitive molecular techniques to quantify low density malaria parasitaemias. J Clin Microbiol. 2014;52:3303-9. doi: 10.1128/JCM.01057-14.
8. Cheng Q, Cunningham J, Gatton ML. Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis. 2015;9:e3413. doi: 10.1371/journal.pntd.0003413.
9. WHO. World Malaria Report. World Health Organization. Geneva. 2014;2014:113.
10. Gray KA, Dowd S, Bain L, Bobogare A, Wini L, Shanks GD, et al. Population genetics of Plasmodium falciparum and Plasmodium vivax and asymptomatic malaria in Temotu Province, Solomon Islands. Malar J. 2013;12:429. doi: 10.1186/1475-2875-12-429.
11. Jennison C, Arnott A, Tessier N, Tavul L, Koepfli C, Felger I, et al. Plasmodium vivax populations are more genetically diverse and less structured than sympatric Plasmodium falciparum populations. PLoS Negl Trop Dis. 2015;9:e0003634. doi: 10.1371/journal.pntd.0003634.
12. Noviyanti R, Coutrier F, Utami RA, Trimarsanto H, Tirta YK, Trianty L, et al. Contrasting transmission dynamics of co-endemic Plasmodium vivax and P. falciparum: implications for malaria control and elimination. PLoS Negl Trop Dis. 2015;9:e0003739. doi: 10.1371/journal.pntd.0003739.
13. Orjuela-Sanchez P, Sa JM, Brandi MC, Rodrigues PT, Bastos MS, Amaratunga C, et al. Higher microsatellite diversity in Plasmodium vivax than in sympatric Plasmodium falciparum populations in Pursat, Western Cambodia. Exp Parasitol. 2013;134:318-26. doi: 10.1016/j.exppara.2013.03.029.
14. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377-410. doi: 10.1128/CMR.00051-10.
15. Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, et al. Malaria resurgence: a systematic review and assessment of its causes. Malar J. 2012;11:122. doi: 10.1186/1475-2875-11-122.
16. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982-91. doi: 10.1016/S1473-3099(14)70855-2.
17. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112. doi: 10.1186/1475-2875-12-112.
18. APMEN. APMEN Asia Pacific Elimination Network. http://apmen.org/. Accessed 24/09/2015.
19. APMEN. APMEN country partners. http://apmen.org/country/. Accessed 24/09/2015.
20. APMEN. Evaluation Report: a mixed method approach using internal and external evaluation 2009-2013. Brisbane, Australia: Asia Pacific Malaria Elimination Network. 2014.
21. RBM. The Asia Pacific Malaria Elimination Network (APMEN) supporting the common goal of a malaria-free Asia Pacific. Progress & impact series, 11. Geneva, Switzerland: Roll Back Malaria Partnership Secretariat, 2014.
22. DFAT. Chairman's Statement of the 9th East Asia Summit. http://dfat.gov.au/international-relations/regional-architecture/eas/Pages/chairmans-statement-of-the-9th-east-asia-summit.aspx. Accessed 14/09/2015.
23. APMEN. Targeting vivax malaria in the Asia Pacific 2009-2014. Brisbane, Australia: Asia Pacific Malaria Elimination Network. 2014.
24. Liu Y, Auburn S, Cao J, Trimarsanto H, Zhou H, Gray KA, et al. Genetic diversity and population structure of Plasmodium vivax in Central China. Malar J. 2014;13:262. doi: 10.1186/1475-2875-13-262.
25. Goo YK, Ji SY, Shin HI, Moon JH, Cho SH, Lee WJ, et al. First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea. PLoS One. 2014;9:e97390. doi: 10.1371/journal.pone.0097390.
26. Hsiang MS, Abeyasinghe R, Whittaker M, Feachem RG. Malaria elimination in Asia-Pacific: an under-told story. Lancet. 2010;375:1586-7. doi: 10.1016/S0140-6736(10)60350-9.
27. ter Kuile FO, Rogerson SJ. Plasmodium vivax infection during pregnancy: an important problem in need of new solutions. Clin Infect Dis. 2008;46:1382-4. doi: 10.1086/586744.
28. WHO. Malaria: draft global technical strategy: post 2015. World Health Organization, Geneva, 2015.
29. RBM. Action and investment to defeat malaria 2016-2030: for a malaria free world. Geneva: World Health Organization; 2015.
30. WHO. Control and elimination of Plasmodium vivax malaria: a technical brief. Geneva: World Health Organization; 2015.
31. Andersen F, Douglas NM, Bustos D, Galappaththy G, Qi G, Hsiang MS, et al. Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades. Malar J. 2011;10:131. doi: 10.1186/1475-2875-10-131.
32. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280. doi: 10.1186/1475-2875-11-280.
33. APMEN. APMEN Advisory Board. http://apmen.org/advisory-board/. Accessed 24/09/2015.
34. Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol. 2000;17:1467-82.
35. Arnott A, Barry AE, Reeder JC. Understanding the population genetics of Plasmodium vivax is essential for malaria control and elimination. Malar J. 2012;11:14. doi: 10.1186/1475-2875-11-14.
36. Preston MD, Campino S, Assefa SA, Echeverry DF, Ocholla H, Amambua-Ngwa A, et al. A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nat Commun. 2014;5:4052. doi: 10.1038/ncomms5052.
37. Rodrigues PT, Alves JM, Santamaria AM, Calzada JE, Xayavong M, Parise M, et al. Using mitochondrial genome sequences to track the origin of imported Plasmodium vivax infections diagnosed in the United States. Am J Trop Med Hyg. 2014;90:1102-8. doi: 10.4269/ajtmh.13-0588.
38. Abdullah NR, Barber BE, William T, Norahmad NA, Satsu UR, Muniandy PK, et al. Plasmodium vivax population structure and transmission dynamics in Sabah Malaysia. PLoS One. 2013;8:e82553. doi: 10.1371/journal.pone.0082553.
39. Daniels R, Chang HH, Sene PD, Park DC, Neafsey DE, Schaffner SF, et al. Genetic surveillance detects both clonal and epidemic transmission of malaria following enhanced intervention in Senegal. PLoS One. 2013;8:e60780. doi: 10.1371/journal.pone.0060780.
40. Ferreira MU, Rodrigues PT. Tracking malaria parasites in the eradication era. Trends Parasitol. 2014;30:465-6. doi: 10.1016/j.pt.2014.08.003.
41. Obaldia N 3rd, Baro NK, Calzada JE, Santamaria AM, Daniels R, Wong W, et al. Clonal Outbreak of Plasmodium falciparum Infection in Eastern Panama. J Infect Dis. 2014;211:1087-96. doi: 10.1093/infdis/jiu575.
42. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol. 2012;28:522-9. doi: 10.1016/j.pt.2012.08.005.
43. Hay SI, Snow RW. The malaria atlas project: developing global maps of malaria risk. PLoS Med. 2006;3:e473. doi: 10.1371/journal.pmed.0030473.
44. Oxford Uo. The Malaria Atlas Project. http://www.map.ox.ac.uk/. Accessed 24/09/2015.
45. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6:e1814. doi: 10.1371/journal.pntd.0001814.
46. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144. doi: 10.1186/1475-2875-13-144.
47. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339. doi: 10.1371/journal.pmed.1001339.
48. Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418. doi: 10.1186/1475-2875-12-418.
49. Elyazar IR, Gething PW, Patil AP, Rogayah H, Sariwati E, Palupi NW, et al. Plasmodium vivax malaria endemicity in Indonesia in 2010. PLoS One. 2012;7:e37325. doi: 10.1371/journal.pone.0037325.
50. The malERA Consultative Group on Monitoring E, and Surveillance. A research agenda for malaria eradication: monitoring, evaluation, and surveillance. PLoS Med. 2011;8:e1000400. doi: 10.1371/journal.pmed.1000400.
51. Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S, Garner P, et al. Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries. Cochrane Database Syst Rev. 2014;12:CD011431. doi: 10.1002/14651858.CD011431.
52. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin Microbiol Infect Dis. 2013;19:399-407. doi: 10.1111/1469-0691.12151.
53. Baird KJ, Maguire JD, Price RN. Diagnosis and treatment of Plasmodium vivax malaria. Adv Parasitol. 2012;80:203-70. doi: 10.1016/B978-0-12-397900-1.00004-9.
54. Kim JY, Ji SY, Goo YK, Na BK, Pyo HJ, Lee HN, et al. Comparison of rapid diagnostic tests for the detection of Plasmodium vivax malaria in South Korea. PLoS One. 2013;8:e64353. doi: 10.1371/journal.pone.0064353.
55. Tao ZY, Zhou HY, Xia H, Xu S, Zhu HW, Culleton RL, et al. Adaptation of a visualized loop-mediated isothermal amplification technique for field detection of Plasmodium vivax infection. Parasit Vectors. 2011;4:115. doi: 10.1186/1756-3305-4-115.
56. Beutler E, Blume KG, Kaplan JC, Lohr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol. 1979;43:465-7.
57. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391. doi: 10.1186/1475-2875-12-391.
58. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. Am J Trop Med Hyg. 2015;. doi: 10.4269/ajtmh.14-0696.
59. LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2014;91:854-61. doi: 10.4269/ajtmh.14-0194.
60. WHO. Point-of Care G6PD testing to suport safe use of primaquine for the treatment of vivax malaria. WHO Evidence Review Group meeting report. Geneva: World Health Organization; 2014.
61. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One. 2011;6:e28357. doi: 10.1371/journal.pone.0028357.
62. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430-5.
63. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010;10:405-16. doi: 10.1016/S1473-3099(10)70079-7.
64. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007;195:934-41. doi: 10.1086/512242.
65. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195:927-33.
66. Craig AA, Kain KC. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J Infect Dis. 1996;174:373-9.
67. Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000;5:755-64.